Narcolepsy can lead to excessive daytime sleepiness, as well as cataplexy, a sudden loss of muscle tone. Other symptoms can include sleep paralysis and hallucinations that occur both during sleep ...

Potential blockbusters and root-cause treatments from Eli Lilly, Merck, Takeda and others could get a regulatory nod this ...

Avadel Pharmaceuticals plc has published six manuscripts in a CNS Drugs supplement titled "A New Dawn in the Management of Narcolepsy," focusing on clinical management strategies, shared ...

The FDA has granted Breakthrough Therapy designation to alixorexton for the treatment of narcolepsy type 1 (NT1).

CHICAGO -- Novel orexin receptor 2 agonist oveporexton normalized wakefulness for most people with narcolepsy type 1 in two randomized phase III trials. Mean sleep latency across four, 40-minute ...

The latest announcement is out from Alkermes ( (ALKS) ).

Alkermes (ALKS) announced that the FDA has granted Breakthrough Therapy Designation to alixorexton, a novel, investigational, ...

AXS-12's clinical development program in narcolepsy includes three controlled efficacy trials, and a completed long-term safety trial. The drug has already been granted orphan drug designation, a ...

DUBLIN, March 25, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals (AVDL) plc , a biopharmaceutical company focused on transforming medicines to transform lives, today announced the publication of six ...

The "United States Narcolepsy Drugs Market to Reach US$ 2,233.56 Million by 2033 - 7.88% CAGR Driven by Novel Therapies and Better Diagnosis" report has been added to ResearchAndMarkets.com's offering ...

Narcolepsy was linked to high blood pressure, hyperlipidemia, and diabetes on top of outright cardiovascular disease events in a retrospective cohort study. Notably, patients with narcolepsy started ...